CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Crispr Therapeutics AG today and set a price target of $93.00. Accordi...

Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over the...

Crispr Therapeutics AG: Stock Surge Amid Challenges

Bernstein analyst William Pickering maintained a Hold rating on Crispr Therapeutics AG yesterday and set a price target of $43.00. The company’s sh...

Bernstein Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made a series of notable trades on Monday, December 1, according to daily fund disclosures. T...

ARKB, HOOD, SHOP, WRD: Cathie Wood Expands Crypto and AI Bets, Trims Stakes in Roku and GitLab (GTLB) Stocks

Crispr Therapeutics AG ( ($CRSP) ) has fallen by -9.20%. Read on to learn why. Crispr Therapeutics AG has experienced a notable decline in its stoc...

Crispr Therapeutics AG Faces Stock Price Slide

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Thursday, November 20, as revealed in daily fun...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRSP	$56.68	-2.43%	1.40M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRSP	$56.68	-2.4%	1.40M
3
4
5
6

CRSP

CRSP

Dividend Overview

Get CRISPR Therapeutics AG Data in Excel

Get CRISPR Therapeutics AG Data in Excel